- Issuer ticker
-
BBNX
- Reported as of
-
27 Feb 2026
- Net transaction value
-
$0
- SEC form
-
4/A - Amendment
- Accepted by SEC
-
13 Mar 2026, 16:15:17 UTC
- Original report date
-
03 Mar 2026
Filing notes and source
Key filing fact
Mark Hopman filed Form 4/A - Amendment for Beta Bionics, Inc. (BBNX) on 13 Mar 2026.
Key facts
- This page summarizes Mark Hopman's Form 4/A - Amendment filing for Beta Bionics, Inc. (BBNX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 Mar 2026, 16:15.
Change
- Previous filing in this sequence was filed on 16 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
View source filing
Reporting Owners (1)
CIK 0002048497
Primary reporting owner
Hopman Mark
- Relationship
-
Chief Commercial Officer
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BBNX
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- Shares
- +91,520
- Change %
- Price
-
$0.000000*
- Shares after
- 91,520
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 91,520
- Exercise price
- $12.63
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote
SEC remarks
The purpose of this amendment is to correct the number of shares underlying the option grant that was reported on the reporting person's original Form 4 filed with the Securities and Exchange Commission on March 3, 2026.